Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANAB NYSE:NUVB NASDAQ:PGEN NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$66.39$60.27$11.40▼$72.36$1.97B0.68627,051 shs400,964 shsNUVBNuvation Bio$5.84+0.5%$5.11$2.06▼$9.75$2.03B1.528.71 million shs6.09 million shsPGENPrecigen$5.32$4.64$1.47▼$6.04$1.90B15.04 million shs3.45 million shsVALNValneva$5.05$5.55$5.04▼$12.25$479.17M1.7718,126 shs16,116 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio0.00%+4.68%+18.41%-3.40%+153.40%NUVBNuvation Bio0.00%+2.71%+19.04%+24.90%+165.41%PGENPrecigen0.00%-5.67%+19.55%+27.58%+190.71%VALNValneva0.00%-3.26%-5.78%-17.62%-16.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANABAnaptysBio$66.39$60.27$11.40▼$72.36$1.97B0.68627,051 shs400,964 shsNUVBNuvation Bio$5.84+0.5%$5.11$2.06▼$9.75$2.03B1.528.71 million shs6.09 million shsPGENPrecigen$5.32$4.64$1.47▼$6.04$1.90B15.04 million shs3.45 million shsVALNValneva$5.05$5.55$5.04▼$12.25$479.17M1.7718,126 shs16,116 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANABAnaptysBio0.00%+4.68%+18.41%-3.40%+153.40%NUVBNuvation Bio0.00%+2.71%+19.04%+24.90%+165.41%PGENPrecigen0.00%-5.67%+19.55%+27.58%+190.71%VALNValneva0.00%-3.26%-5.78%-17.62%-16.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANABAnaptysBio 2.69Moderate Buy$81.8223.24% UpsideNUVBNuvation Bio 2.64Moderate Buy$12.38111.94% UpsidePGENPrecigen 2.33Hold$12.50134.96% UpsideVALNValneva 2.20Hold$11.98137.13% UpsideCurrent Analyst Ratings BreakdownLatest VALN, ANAB, NUVB, and PGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026NUVBNuvation Bio Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $19.007/7/2026NUVBNuvation Bio Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $13.007/6/2026NUVBNuvation Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/18/2026VALNValneva Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/10/2026NUVBNuvation Bio CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/10/2026ANABAnaptysBio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$95.006/2/2026ANABAnaptysBio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/28/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $14.005/26/2026NUVBNuvation Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/15/2026ANABAnaptysBio Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$90.005/14/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.00(Data available from 7/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANABAnaptysBio$234.60M8.38N/AN/A$1.34 per share49.54NUVBNuvation Bio$143.05M14.21N/AN/A$0.88 per share6.64PGENPrecigen$9.68M195.93N/AN/A$0.06 per share88.67VALNValneva$156.33M3.07N/AN/A$1.39 per share3.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANABAnaptysBio-$13.23M-$1.08N/A20.43N/A-11.53%N/A-7.75%8/5/2026 (Estimated)NUVBNuvation Bio-$204.63M-$0.43N/AN/AN/A-102.06%-44.10%-23.80%8/6/2026 (Estimated)PGENPrecigen-$250.64M-$1.18N/A21.28N/A-646.99%717.50%58.48%8/11/2026 (Estimated)VALNValneva-$130.33M-$1.87N/A2.67N/A-88.87%-107.63%-33.02%8/11/2026 (Estimated)Latest VALN, ANAB, NUVB, and PGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NUVBNuvation Bio-$0.15N/AN/AN/A$26.88 millionN/A8/5/2026Q2 2026ANABAnaptysBio-$0.1273N/AN/AN/A$20.22 millionN/A5/13/2026Q1 2026PGENPrecigen-$0.03-$0.02+$0.01-$0.02$20.81 million$23.25 million5/13/2026Q1 2026VALNValneva-$0.1485-$0.42-$0.2715-$0.42$54.69 million$36.16 million5/12/2026Q1 2026ANABAnaptysBio-$0.6436-$1.84-$1.1965-$1.84$18.86 million$25.56 million5/4/2026Q1 2026NUVBNuvation Bio-$0.0280$0.01+$0.0380$0.01$66.22 million$83.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANABAnaptysBioN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANABAnaptysBioN/A7.587.58NUVBNuvation Bio0.157.447.24PGENPrecigen4.624.824.12VALNValneva2.142.141.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANABAnaptysBioN/ANUVBNuvation Bio61.67%PGENPrecigen33.51%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipANABAnaptysBio31.50%NUVBNuvation Bio30.11%PGENPrecigen41.40%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANABAnaptysBio10029.61 million20.28 millionOptionableNUVBNuvation Bio60348.20 million243.36 millionOptionablePGENPrecigen190356.51 million208.92 millionOptionableVALNValneva70094.89 million80.74 millionNot OptionableVALN, ANAB, NUVB, and PGEN HeadlinesRecent News About These CompaniesValneva SE Sponsored ADRJuly 11 at 10:33 PM | cnn.comValneva SE Sponsored ADR (NASDAQ:VALN) Receives $11.97 Consensus Target Price from BrokeragesJuly 11 at 10:41 AM | americanbankingnews.comValneva (NASDAQ:VALN) vs. High Tide (NASDAQ:HITI) Head to Head ContrastJuly 10 at 3:41 AM | americanbankingnews.comExperimental vaccine shows promise against dangerous intestinal illnessJuly 7, 2026 | msn.comIf a Lyme disease vaccine gets approved, how would it go over? We asked huntersJune 28, 2026 | msn.comNew research may lead to a vaccine against severe diarrheaJune 26, 2026 | medicalxpress.comMValneva SE (VALN) Shareholder/Analyst Call - SlideshowJune 25, 2026 | seekingalpha.comResearch may help pave the way for new vaccine targeting diarrheal diseaseJune 25, 2026 | news-medical.netNValneva SE (VALN) Shareholder/Analyst Call Prepared Remarks TranscriptJune 25, 2026 | seekingalpha.comValneva Announces Successful Outcome of its Annual General MeetingJune 25, 2026 | globenewswire.comValneva Announces Availability of Documentation for its Annual General MeetingJune 4, 2026 | globenewswire.comVALNEVA:Declaration of shares and voting rights - Status as of May 31, 2026June 3, 2026 | finance.yahoo.comValneva annonce sa participation à des conférences investisseurs aux États-Unis et en EuropeMay 28, 2026 | globenewswire.comValneva to Participate at U.S. and European Investor Conferences in JuneMay 28, 2026 | globenewswire.comValneva SE 2026 Q1 - Results - Earnings Call PresentationMay 16, 2026 | seekingalpha.comValneva SE (VALN) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comValneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ...May 13, 2026 | uk.finance.yahoo.comValneva to lay off up to 15% of workforce in face of ‘adverse trend’ in travel vaccinesMay 13, 2026 | fiercebiotech.comFValneva Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 13, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALNMay 7, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVALN, ANAB, NUVB, and PGEN Company DescriptionsAnaptysBio NASDAQ:ANAB$66.39 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$66.39 0.00 (0.00%) As of 06:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Nuvation Bio NYSE:NUVB$5.84 +0.03 (+0.50%) Closing price 07/10/2026 03:59 PM EasternExtended Trading$5.82 -0.01 (-0.24%) As of 06:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Precigen NASDAQ:PGEN$5.32 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$5.38 +0.06 (+1.20%) As of 04:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Valneva NASDAQ:VALN$5.05 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$5.14 +0.09 (+1.86%) As of 06:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
